Cargando…
Sacituzumab govitecan and other antibody-drug conjugates targeting trophoblast cell-surface antigen 2 (Trop-2) in breast cancer
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577799/ https://www.ncbi.nlm.nih.gov/pubmed/36267779 http://dx.doi.org/10.21037/atm-22-1892 |
| _version_ | 1784811840418611200 |
|---|---|
| author | Matusz-Fisher, Ashley Tan, Antoinette R. |
| author_facet | Matusz-Fisher, Ashley Tan, Antoinette R. |
| author_sort | Matusz-Fisher, Ashley |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9577799 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-95777992022-10-19 Sacituzumab govitecan and other antibody-drug conjugates targeting trophoblast cell-surface antigen 2 (Trop-2) in breast cancer Matusz-Fisher, Ashley Tan, Antoinette R. Ann Transl Med Editorial Commentary AME Publishing Company 2022-09 /pmc/articles/PMC9577799/ /pubmed/36267779 http://dx.doi.org/10.21037/atm-22-1892 Text en 2022 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Editorial Commentary Matusz-Fisher, Ashley Tan, Antoinette R. Sacituzumab govitecan and other antibody-drug conjugates targeting trophoblast cell-surface antigen 2 (Trop-2) in breast cancer |
| title | Sacituzumab govitecan and other antibody-drug conjugates targeting trophoblast cell-surface antigen 2 (Trop-2) in breast cancer |
| title_full | Sacituzumab govitecan and other antibody-drug conjugates targeting trophoblast cell-surface antigen 2 (Trop-2) in breast cancer |
| title_fullStr | Sacituzumab govitecan and other antibody-drug conjugates targeting trophoblast cell-surface antigen 2 (Trop-2) in breast cancer |
| title_full_unstemmed | Sacituzumab govitecan and other antibody-drug conjugates targeting trophoblast cell-surface antigen 2 (Trop-2) in breast cancer |
| title_short | Sacituzumab govitecan and other antibody-drug conjugates targeting trophoblast cell-surface antigen 2 (Trop-2) in breast cancer |
| title_sort | sacituzumab govitecan and other antibody-drug conjugates targeting trophoblast cell-surface antigen 2 (trop-2) in breast cancer |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577799/ https://www.ncbi.nlm.nih.gov/pubmed/36267779 http://dx.doi.org/10.21037/atm-22-1892 |
| work_keys_str_mv | AT matuszfisherashley sacituzumabgovitecanandotherantibodydrugconjugatestargetingtrophoblastcellsurfaceantigen2trop2inbreastcancer AT tanantoinetter sacituzumabgovitecanandotherantibodydrugconjugatestargetingtrophoblastcellsurfaceantigen2trop2inbreastcancer |